Last updated at 30 Jun 2024 11:47 PM
Director
DIN: 08563139
Dhruv Desai is currently associated with 2 companies in various capacities such as Individual Promoter and Director. They serve as a Director at CELLIIMUNE THERAPEUTICS PRIVATE LIMITED and have other roles in different companies. They are registered with the Ministry of Corporate Affairs (MCA) of India and hold a DIN of 08563139.Dhruv Desai has previously been associated with 2 companies in roles such as Director.Dhruv Desai is currently involved in 2 different roles. Their most recent position is with AXGEN CHEMICALS PRIVATE LIMITED as a Director. The first company Dhruv Desai was appointed to as a director was CELLIIMUNE THERAPEUTICS PRIVATE LIMITED. Dhruv Desai is not disqualified by the Registrar of Companies under Section 164(2), and their DIN has not been deactivated due to failure to file the DIR-3 KYC Form.
Dhruv Desai is currently associated with 2 companies in various capacities such as Individual Promoter and Director. They serve as a Director at CELLIIMUNE THERAPEUTICS PRIVATE LIMITED and have other roles in different companies. They are registered with the Ministry of Corporate Affairs (MCA) of India and hold a DIN of 08563139.Dhruv Desai has previously been associated with 2 companies in roles such as Director.Dhruv Desai is currently involved in 2 different roles. Their most recent position is with AXGEN CHEMICALS PRIVATE LIMITED as a Director. The first company Dhruv Desai was appointed to as a director was CELLIIMUNE THERAPEUTICS PRIVATE LIMITED. Dhruv Desai is not disqualified by the Registrar of Companies under Section 164(2), and their DIN has not been deactivated due to failure to file the DIR-3 KYC Form.
2
Male
India
Gain instant access to verified contact details.
Current Companies (2)
Current LLPs (0)
Past Companies (2)
1y 3m 8 Months Interval
| Company Name | Designation | Date of Appointment |
|---|---|---|
| CELLIIMUNE THERAPEUTICS PRIVATE LIMITED | Individual Promoter | 26-May-2022 |
| AXGEN CHEMICALS PRIVATE LIMITED | Director | 22-Jun-2024 |